Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Intermediate-stage Hepatocellular Carcinoma

NCT02435953 is registered in ClinicalTrials.gov with Ming Zhao as lead sponsor.

NCT NCT02435953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02435953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Intermediate-stage Hepatocellular Carcinoma
Lead sponsor
Ming Zhao
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2015
Completion date
October 31, 2025
Enrollment
241 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ablation techniques, rfa, chemoembolization, therapeutic, hepatocellular carcinoma